MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/85/0.1/20.06.25 | Real-time Bid/Ask 02:13:55 21/06/2024 pm IST | ||
| 0.51 EUR / 0.57 EUR | +5.88% |
|
| Current month | +2.00% | ||
| 1 month | +21.43% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 20/24/20 | 0.51 | +4.08% |
| 19/24/19 | 0.49 | -5.77% |
| 18/24/18 | 0.52 | -8.77% |
| 17/24/17 | 0.57 | -5.00% |
| 14/24/14 | 0.6 | +3.45% |
Delayed Quote Börse Stuttgart
Last update June 20, 2024 at 10:16 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | ME5FKP |
| ISIN | DE000ME5FKP4 |
| Date issued | 15/12/2023 |
| Strike | 85 $ |
| Maturity | 20/06/2025 (365 Days) |
| Parity | 10 : 1 |
| Emission price | 0.24 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.62 € |
|---|---|
| Lowest since issue | 0.08 € |
| Spread | 0.06 € |
| Spread % | 10.91% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.2
USD
Average target price
174.4
USD
Spread / Average Target
+11.00%
- Stock Market
- Warrants
- Warrant
